The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric ...

Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®?(Dengue ...

Discover Rhythm Pharmaceuticals’ Q3 2025 earnings insights, IMCIVREE launch updates, regulatory milestones, and global growth plans.

Research led by the University of Jyväskylä has found that personalized interactive music systems – smart technologies that adapt rhythm and tempo to ...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth ...

Research led by the University of Jyväskylä has found that personalized interactive music systems—smart technologies that ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option.1 ...

This study links childhood gut microbiome to brain connectivity, highlighting its role in internalizing symptoms like anxiety ...

Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...